In the final analysis from KEYNOTE-177, first-line pembrolizumab was associated with an improved median OS compared with chemotherapy in patients with MSI-H/dMMR mCRC.
In previously untreated patients with advanced gastroesophageal cancers, nivolumab plus chemotherapy significantly prolonged OS and PFS vs chemotherapy alone.
Compared with placebo, adjuvant nivolumab significantly prolonged disease-free survival in patients with resected EC/GEJC who had received neoadjuvant chemotherapy.
Interim analysis of the KEYNOTE-811 trial shows significantly higher response rate and more durable responses with pembrolizumab added to first-line trastuzumab and chemotherapy in gastric or gastroesophageal junction cancer.
In patients with advanced esophageal cancer and no previous therapy for advanced disease, nivolumab with either ipilimumab or chemotherapy significantly increased overall survival vs chemotherapy alone.